Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms
(Source: Abbott.com)
Source: Abbott.com - December 2, 2020 Category: Pharmaceuticals Source Type: news
Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes
- Abbott is committing $5 million over three years to the American Diabetes Association (ADA) to help close the health disparities gap for underserved diabetes communities, especially people of color and lower-income Americans (Source: Abbott.com)
Source: Abbott.com - November 18, 2020 Category: Pharmaceuticals Source Type: news
Abbott Launches the First Infant Formula in Canada with an Ingredient Identical in Structure to Immune Component Found in Breast Milk
(Source: Abbott.com)
Source: Abbott.com - November 17, 2020 Category: Pharmaceuticals Source Type: news
Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)
- Abbott achieves top industry scores in governance/economic and social performance, earns more than triple the average industry score in its industry sector (Source: Abbott.com)
Source: Abbott.com - November 16, 2020 Category: Pharmaceuticals Source Type: news
Abbott Announces the U.S. Launch of the IonicRF ™ Generator for Use in Patients Living With Chronic Pain
-- Radiofrequency ablation is a minimally invasive procedure to deactivate nerves associated with pain for up to one year (Source: Abbott.com)
Source: Abbott.com - November 10, 2020 Category: Pharmaceuticals Source Type: news
Abbott Introduces Next-generation 3D Cardiac Mapping Platform in Europe and Australia
- The EnSite ™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures (Source: Abbott.com)
Source: Abbott.com - November 2, 2020 Category: Pharmaceuticals Source Type: news
Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip ™ Device
-- Considered as the industry's equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020 (Source: Abbott.com)
Source: Abbott.com - October 30, 2020 Category: Pharmaceuticals Source Type: news
Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
- Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent (Source: Abbott.com)
Source: Abbott.com - October 21, 2020 Category: Pharmaceuticals Source Type: news
Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows
- New research from the University of Illinois, Urbana-Champaign, Abbott, and U.S. Air Force published in the journal Scientific Reports demonstrates that the right nutrition is directly linked to physical and cognitive performance in active duty men and women in the U.S. Air Force (Source: Abbott.com)
Source: Abbott.com - October 19, 2020 Category: Pharmaceuticals Source Type: news
New Late-Breaking Data Show Equivalent Outcomes with Shorter Durations of Anti-Clotting Drugs for XIENCE ™ Stent Patients with High Bleeding Risk
- Results from Abbott ’s XIENCE™ 28 and XIENCE 90 trials demonstrate non-inferiority of shorter courses of dual antiplatelet therapy in reducing the frequency of post-stenting death, heart attacks and severe bleeding compared with 12 months of dual antiplatelet therapy in patients with high bleeding risk (Source: Abbott.com)
Source: Abbott.com - October 15, 2020 Category: Pharmaceuticals Source Type: news
Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test
- Data demonstrates highly reliable test results with 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset (Source: Abbott.com)
Source: Abbott.com - October 12, 2020 Category: Pharmaceuticals Source Type: news
Abbott Releases ID NOW ™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health
- Data show ID NOW performance of 95.0% sensitivity and 97.9% specificity within seven days of symptom onset (Source: Abbott.com)
Source: Abbott.com - October 7, 2020 Category: Pharmaceuticals Source Type: news
Abbott Enrolls First Patient in Study to Investigate BurstDR ™ Stimulation to Treat Non-operative Low Back Pain
- Low back pain affects one in 10 Americans and often impacts the patient physically, emotionally and economically (Source: Abbott.com)
Source: Abbott.com - September 30, 2020 Category: Pharmaceuticals Source Type: news
Abbott's FreeStyle ® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes
- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people with diabetes (Source: Abbott.com)
Source: Abbott.com - September 28, 2020 Category: Pharmaceuticals Source Type: news
Abbott Receives CE Mark for Next-Generation MitraClip ™ Heart Valve Repair Device to Treat Mitral Regurgitation
- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology (Source: Abbott.com)
Source: Abbott.com - September 21, 2020 Category: Pharmaceuticals Source Type: news
